Tempus Stock

Tempus is a technology-driven company that specializes in AI-enabled precision medicine, focusing on oncology, neurology, psychiatry, and cardiology. The company offers genomic profiling, which provides detailed insights into a patient's genetic makeup, and algorithmic tests to predict treatment efficacy. Additionally, Tempus facilitates clinical trial matching to connect patients with potentially life-saving therapies. Collaborating extensively with academic medical centers and biopharma companies, Tempus boasts over 200 partnerships. Their advanced technology includes the AI-enabled clinical assistant Tempus One, which integrates multimodal data for comprehensive patient insights. Digital pathology solutions and real-world data applications further enhance diagnostics and treatments. Tempus' database includes over 6 million de-identified research records, significantly contributing to scientific discovery and improved patient outcomes. Notably, their HLA-LOH companion diagnostic test has received FDA Breakthrough Device designation, underscoring their impact in the field of precision medicine.